Experts call for universal genetic testing in metastatic prostate cancer

By staff writers

June 11, 2020 -- All men with metastatic prostate cancer or a family history suggesting hereditary risk should be getting genetic testing, experts recommended in an article published June 9 in the Journal of Clinical Oncology.

The article from Dr. Veda Giri of Sidney Kimmel Cancer Center at Thomas Jefferson University and colleagues reflects a review of germline and somatic testing in prostate cancer discussed at an international multidisciplinary consensus conference held October 4 to 5. The meeting – the Philadelphia Prostate Cancer Consensus Conference 2019: Implementation of Germline Testing for Prostate Cancer, was hosted by Sidney Kimmel Cancer Center at Thomas Jefferson University.

To ensure access to personalized treatments and clinical trials, stakeholders at the meeting called for testing all men with metastatic prostate cancer and also men with a family history that suggests hereditary risk for prostate cancer and other tumor types. According to the group, large germline panels and somatic testing are recommended and screening for certain mutations should be prioritized: BRCA1, BRCA2, and DNA mismatch repair genes.

Routine use of genetic testing has real-world implications for patients as two poly (ADP-ribose) polymerase (PARP) inhibitors were just approved for subtypes of metastatic castration-resistant prostate cancer. Last month, the U.S. Food and Drug Administration approved rucaparib (Rubraca) for patients with germline or somatic BRCA mutations and olaparib (Lynparza) in those with germline or somatic homologous recombination repair-mutated disease.

Despite its value in finding mutations that are actionable, however, genetic testing of men for prostate cancer is "still not common practice due to inconsistent guidelines and challenges to implementation of genetic counseling," conference sponsors said in a statement about the just-published recommendations.

Study finds genetic prostate cancer screening feasible
Research presented at the recent American Society of Clinical Oncology virtual conference has shown that genetic screening for prostate cancer is feasible...
Survey: Molecular testing greatly underused in lung cancer patients
Molecular testing is greatly underused in patients with non-small cell lung cancer for a variety of reasons, including cost, concerns about quality, turnaround...
Less prostate-specific antigen testing linked with more advanced tumors
Less prostate-specific antigen testing in the wake of guidelines that discouraged use was linked to a drop in diagnosis of early-stage disease and more...
BRCA status leads the way in screening men for prostate cancer
Blood testing for levels of prostate-specific antigen gets a bad rap, but a targeted approach is gaining support. A large study published online September...
USPSTF calls for more BRCA1/2 genetic screening, testing
Broader recommendations on screening for BRCA1/2 genetic mutations published by the U.S. Preventive Services Task Force (USPSTF) on August 20 represent...

Copyright © 2020

Last Updated ls 6/11/2020 12:38:26 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.